Prometheus

PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

Retrieved on: 
Monday, May 22, 2023
Biotechnology, Legal, Professional Services, Health, Prometheus, Merck, MRK, Merck & Co., KSF, NYSE, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK).
  • Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Mindera Health™ Announces Change to Executive Leadership Team

Retrieved on: 
Thursday, May 11, 2023
Lupus, Gastroenterology, Employment, Prognosis, XGN, SLE, Biomarker, Psoriasis, Towson University, Acquisition, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Patient, Physician, Medicine, R, Health, III, Human, Rheumatoid arthritis, Disease, Management, Pharmaceutical industry, Prometheus, Marketing

San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.

Key Points: 
  • San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.
  • The company has announced industry veteran Ron Rocca will succeed George Mahaffey as President and Chief Executive Officer.
  • Mr. Mahaffey, who joined the company in 2020, helped lead the company’s transition from the R&D stage through the commercial launch of Mindera Health’s first test.
  • “On behalf of the board, I want to thank George for his valuable contributions to Mindera Health,” said Joe Cook, III, Chairman of Mindera Health and Co-Founder and Managing Director of Mountain Group Partners.

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Tuesday, May 9, 2023
Prometheus, Therapy, Investment, Administration, SAN, Medicine, Merck, Research and development, R, Research, Pharmaceutical industry, Cryptocurrency

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023.
  • The transaction is expected to close in the third quarter of 2023.
  • As of March 31, 2023, Prometheus Biosciences had cash, cash equivalents and short-term investments of $713.7 million, compared to $695.8 million at the end of Q4 2022.
  • Research and development expenses were $36.4 million for the three months ended March 31, 2023 compared to $27.9 million for the three months ended March 31, 2022.

Grafana Labs Announces New Tools for Metrics Cost Management in Grafana Cloud

Retrieved on: 
Tuesday, May 9, 2023
Networks, Internet, Data Management, Technology, Software, Cloud, Prometheus, Organization, Cardinality, SRE, Education minister, Environment, GB, Video game, Rare-earth element, Telescopic sight, Internet service provider

This feature leverages enhanced insights into metrics usage recently added to Grafana Cloud's Cardinality Management dashboards, which are now available in all Grafana Cloud tiers, both free and paid.

Key Points: 
  • This feature leverages enhanced insights into metrics usage recently added to Grafana Cloud's Cardinality Management dashboards, which are now available in all Grafana Cloud tiers, both free and paid.
  • The Cardinality Management dashboards were first introduced late last year to Grafana Cloud Pro and Advanced customers, but now are generally available to all Grafana Cloud users, including those on the Grafana Cloud Free tier.
  • Grafana Cloud Adaptive Metrics is now available in a public access program for all Grafana Cloud tiers.
  • "In fact, we even had this problem at Grafana Labs, running our own Prometheus monitoring for Grafana Cloud.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, CVT, RADI, INFI

Retrieved on: 
Thursday, May 4, 2023
Prometheus, Sale, Blackstone, EQT, Advertising, Infinity, Cvent, Fraud, Security (finance), Merck

If you are a Prometheus shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Prometheus shareholder, click here to learn more about your rights and options .
  • If you are a Cvent shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)

Retrieved on: 
Wednesday, May 3, 2023
Prometheus, GSK, Tripura Merger Agreement, Brodsky, MRK, Darden, DRI, Dianthus, Darden Restaurants, NYSE, GSK plc, Security (finance), Pharmaceutical industry, Merck

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Ruth’s will be acquired by Darden Restaurants, Inc. (“Darden”) (NYSE - DRI).
  • Ruth’s shareholders will receive $21.50 in cash for each share of Ruth’s they own for a total equity value of approximately $715 million.
  • Prometheus shareholders will receive $200.00 cash for each Prometheus common share, for a total equity value of approximately $10.8 billion.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

Retrieved on: 
Monday, May 1, 2023
Prometheus, ASRT, GSK, Tripura Merger Agreement, APO, Brodsky, MRK, Univar Solutions, Assertio Therapeutics, NYSE, GSK plc, Security (finance), Pharmaceutical industry, Merck, Spectrum

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Merger Agreement, Spectrum will be acquired by Assertio Holdings, Inc. (“Assertio”) (Nasdaq - ASRT).
  • BELLUS shareholders will receive $14.75 cash for each BELLUS common share, for a total equity value of approximately $2.0 billion.
  • Prometheus shareholders will receive $200.00 cash for each Prometheus common share, for a total equity value of approximately $10.8 billion.

Mezmo Announces Free Access to Telemetry Pipeline

Retrieved on: 
Wednesday, April 26, 2023
Elastic, GCP, JavaScript, SAN, Digital, Azure, AWS, Telemetry, Oil, Prometheus, Splunk

SAN FRANCISCO, April 26, 2023 (GLOBE NEWSWIRE) -- Mezmo, the leading observability data platform , today announced a free trial and a free community plan for Mezmo Telemetry Pipeline.

Key Points: 
  • SAN FRANCISCO, April 26, 2023 (GLOBE NEWSWIRE) -- Mezmo, the leading observability data platform , today announced a free trial and a free community plan for Mezmo Telemetry Pipeline.
  • Mezmo’s Telemetry Pipeline is changing the data landscape, making it easier for teams to collect, transform, and route telemetry data to control costs and get the most value from their telemetry data.
  • “We want to lower the barrier for entry and show companies how Mezmo’s Telemetry Pipeline can help them control costs and transform their data to drive action.”
    Since the initial launch, Mezmo has added many capabilities to its telemetry pipeline, providing better control and user experience.
  • Mezmo is bringing to market innovative solutions to meet the growing demand for wider access, more control, and easy usage of telemetry data.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)

Retrieved on: 
Tuesday, April 25, 2023
Prometheus, ASRT, GSK, Tripura Merger Agreement, APO, Brodsky, MRK, Univar Solutions, Assertio Therapeutics, NYSE, GSK plc, Security (finance), Pharmaceutical industry, Merck, Spectrum

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Merger Agreement, Spectrum will be acquired by Assertio Holdings, Inc. (“Assertio”) (Nasdaq - ASRT).
  • BELLUS shareholders will receive $14.75 cash for each BELLUS common share, for a total equity value of approximately $2.0 billion.
  • Prometheus shareholders will receive $200.00 cash for each Prometheus common share, for a total equity value of approximately $10.8 billion.

Antelope Leap v4.0.0 Released: Delivering Speed, Scalability, and Reliability

Retrieved on: 
Tuesday, April 25, 2023
EOS, Block, API, EFN, Directory, RPC, ENF, Ecosystem, WAX, News, NodeOS, Cryptocurrency, Prometheus, Telegraphy, Antelope, LEAP

Due to it's reputation as a leading platform for blockchain projects that prioritize performance, scalability, and reliability, EOS quickly spawned other networks built on its underlying technology, called Antelope.

Key Points: 
  • Due to it's reputation as a leading platform for blockchain projects that prioritize performance, scalability, and reliability, EOS quickly spawned other networks built on its underlying technology, called Antelope.
  • In 2022, the ENF stewarded the formation of the Antelope coalition, together with three other leading blockchain networks built on Antelope, Telos , UX Network and WAX .
  • Since then, the ENF has delivered a non-stop stream of exciting developments for the open-source codebase of both EOS and Antelope.
  • Be sure to follow the EOS Network Foundation and Antelope Twitter to stay in the loop on future releases.